Celldex Therapeutics, Inc.
CLDX presented final results yesterday from a Phase 1 study of
CDX-301 (recombinant human Flt3L; rhuFlt3L) in healthy volunteers that
strongly support the initiation of a pilot study in hematopoietic stem cell
transplantation later this year. The data were presented by Michael Yellin,
MD, Vice President of Clinical Science at Celldex, in an oral presentation at
the American Society for Blood and Marrow Transplantation 2013 BMT Tandem
Meetings. The study was conducted at Rockefeller University by Niroshana
Anandasabapathy, MD, PhD, who worked as an instructor in clinical
investigation in the laboratory of the late Nobel Laureate Ralph Steinman, MD.
"The final results from this study are consistent with previous clinical
experience and demonstrate that CDX-301 is well-tolerated and can effectively
mobilize hematopoietic stem cell populations as a single agent in healthy
volunteers," said Dr. Yellin. "Based on the safety profile and the impressive
increases observed for CD34+ stem cells and dendritic cells, we believe
CDX-301 holds significant promise in both the allogeneic and autologous
transplant setting, including the potential for combination with other
molecules that could work in synergy with CDX-301 to further enhance the
mobilization of hematopoietic stem cell populations. Published pre-clinical
Flt3L studies also suggest that CDX-301 could potentially improve engraftment
and reduce the risk of graph versus host disease. This may be especially
important for older patients and patients who are in poor health."
Study results:
30 healthy volunteers were enrolled across seven cohorts. The first five
cohorts assessed escalating doses of CDX-301 (from 1 mcg/kg to 75 mcg/kg) as a
five-day regimen, while the final two cohorts assessed CDX-301 (at 25 mcg/kg)
as seven- and 10-day regimens. All volunteers completed dosing and safety
follow-up. Short-term dosing of five days resulted in a median of 10-fold
increases in CD34+ cells—stem cells that have the ability to give rise to all
cell types in the blood. Of note, on day 10 of dosing, a greater than 100-fold
increase in dendritic cells—cells believed to play a critical role in the
long-term improvement of transplant outcome—was observed in the peripheral
blood. CDX-301 was generally well-tolerated with transient grade 1
lymphadenopathy observed in six volunteers (all treated at the highest dose
levels of 25 mcg/kg and 75 mcg/kg). No anti-CDX-301 antibodies were detected
in any volunteers through the end of study follow-up.
CDX-301 or rhuFlt3L is a potent cytokine that stimulates the expansion and
differentiation of hematopoietic progenitor and stem cells. rhuFlt3L has
demonstrated a unique capacity to increase the number of circulating dendritic
cells in both laboratory and clinical studies. In addition, rhuFlt3L has shown
impressive results in models of cancer, infectious diseases and
inflammatory/autoimmune diseases. The clinical safety and activity of rhuFlt3L
were originally demonstrated by Immunex (now Amgen) in clinical trials
involving more than 150 healthy volunteers and 380 patients with cancer.
Recognizing the promise of CDX-301, Celldex in-licensed the program from Amgen
in 2009. Celldex's completion of this recent Phase 1 study confirms and builds
upon the extensive prior clinical experience and reaffirms the significant
potential for CDX-301.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in